RxDoctor Payments Data

Valerie Mayuga, MD

Family Medicine · Chicago, ILNPI 1740697853

Payments from drug & device makers

$738in general payments, 2019–2025

Across 9 payments — averaging $81.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$223
  • Novartis$190
  • Phathom Pharmaceuticals, Inc.$104
  • Medtronic$94
  • Bayer$89
  • Sanofi$20
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$223
Novartis2$190
Phathom Pharmaceuticals, Inc.1$104
Medtronic1$94
Bayer1$89
Sanofi1$20
Amgen1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$144,767
Medicare patients
290
Services billed
1,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$16,101
OzempicSemaglutide13$13,380
XareltoRivaroxaban21$11,576
EntrestoSacubitril/Valsartan14$6,014
SymbicortBudesonide/Formoterol Fumarate11$2,657
Memantine Hcl35$2,216
Lidocaine15$2,056
Enoxaparin Sodium14$1,784
Albuterol Sulfate HfaAlbuterol Sulfate54$1,723
Tamsulosin Hcl75$1,401
Alcohol Prep PadsAlcohol Antiseptic Pads22$1,349
Nifedipine ErNifedipine82$1,285
Atorvastatin Calcium101$1,186
LantusInsulin Glargine,hum.Rec.Anlog17$1,109
Valproic AcidValproic Acid (As Sodium Salt)19$1,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$190$6,01414 claims
AstraZenecaSymbicort$223$2,65711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →